FdaApplication
BLA 125741
Identifiers
- fda_app_no: BLA125741
Properties
| Property | Value |
|---|---|
| applicant_name | Merck Sharp & Dohme LLC |
| application_type | BLA |
| approval_date | 2021-07-16 |
Revenue by product
VAXNEUVANCE
| Period | Revenue |
|---|---|
| Q2 2026 | $148.0M |
| Q1 2026 | $202.0M |
| Q4 2025 | $140.0M |
| Q3 2025 | $226.0M |
| Q2 2025 | $229.0M |
| Q1 2025 | $230.0M |
| Q4 2024 | $161.0M |
| Q3 2024 | $239.0M |
| Q2 2024 | $189.0M |
| Q1 2024 | $219.0M |
| Q4 2023 | $177.0M |
| Q3 2023 | $214.0M |
| Q2 2023 | $168.0M |
| Q1 2023 | $106.0M |
| Q4 2022 | $138.0M |
| Q3 2022 | $16.0M |
| Q2 2022 | $12.0M |
| Q1 2022 | $5.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VAXNEUVANCE | — | 2.0UG | Injection |
1 product